Abbott (NYSE: ABT) released its fourth-quarter and full-year 2025 financial results today, reporting double-digit earnings growth and issuing a bullish outlook for 2026. The healthcare giant’s performance was bolstered by a surge in its Medical Devices division and strategic expansions into the cancer diagnostics market.
2025 Financial Highlights
For the full year 2025, Abbott reported total sales of $44.3 billion, a 5.7% increase on a reported basis. Excluding the impact of declining COVID-19 testing sales, organic sales growth for the year stood at a robust 6.7%.
Earnings also saw a significant climb:
- Full-Year Adjusted Diluted EPS: $5.15, representing 10% growth over 2024.
- Fourth-Quarter Adjusted Diluted EPS: $1.50, up 12% compared to the same period last year.
- Fourth-Quarter Total Sales: $11.46 billion, a 4.4% reported increase.
Read More: Johnson & Johnson Reports Record Q4 and 2025 Results; Targets $100 Billion Milestone for 2026
Medical Devices and Pharmaceuticals Drive Results
The Medical Devices segment remained the company’s primary growth engine, with sales jumping 12.3% in the fourth quarter. Growth was led by:
- Diabetes Care: Continuous Glucose Monitoring (CGM) sales reached $2.0 billion in Q4 alone, a 15% reported increase.
- Electrophysiology & Heart Failure: Both sub-segments saw double-digit gains, supported by new regulatory milestones.
Strategic Shifts and Acquisitions
A major focal point for the year was Abbott’s agreement to acquire Exact Sciences, a move intended to establish Abbott as a leader in the rapidly growing cancer diagnostics field. The transaction is expected to close in the second quarter of 2026.
The company also advanced its leadership in heart health technology with two key approvals:
- Volt™ PFA System: Received U.S. FDA approval in December, marking Abbott’s first pulsed field ablation offering in the U.S.
- TactiFlex™ Duo: Obtained the CE Mark in January for treating atrial fibrillation using dual-energy (RF and PFA) technology.
Navigating Challenges in Nutrition and Diagnostics
While other segments soared, the Nutrition division saw an 8.9% decline in Q4 sales. Management attributed this to lower sales volumes and “strategic price actions” designed to stimulate future volume growth. Similarly, the Diagnostics segment faced a 2.5% decline as COVID-19 testing demand continued to normalize (falling to $89 million in Q4 from $176 million a year prior) and market conditions in China remained challenging.
2026 Outlook: Looking Ahead
Abbott issued an optimistic forecast for 2026, projecting:
- Organic Sales Growth: 6.5% to 7.5% (excluding COVID-19 testing).
- Adjusted Diluted EPS: $5.55 to $5.80, which would represent another 10% growth at the midpoint.
Investors reacted positively to the guidance, as the company’s focus on high-growth areas like cancer diagnostics and advanced heart-mapping technology appears to be offsetting the post-pandemic decline in testing revenues.
Last Update:
